Harbin focuses on cracking down on the use of fake and inferior traditional Chinese Medicine

Recently, SFDA launched a one and a half month special inspection on the extraction and extract use in the production of traditional Chinese medicine for 65 Chinese patent medicine manufacturers in the city, focusing on cracking down on serious violations such as the use of fake and inferior traditional Chinese medicine as pharmaceutical raw materials, and will take back their GMP certification for enterprises with serious violations This inspection focuses on the largest production and sales volume, the entrusted extraction (the group shares the extraction workshop) and the types of extracts specified in the prescription, and spot checks all finished products in 2013 and 2014 and all batches of Chinese herbal medicines, Chinese herbal pieces and Chinese herbal extracts involved We will focus on cracking down on such serious violations as unauthorized extraction, illegal use of Chinese herbal extracts instead of Chinese herbal medicines, purchase of non-conforming Chinese herbal extracts, use of fake and inferior Chinese herbal medicines, non-medical parts of Chinese herbal medicines and other non-conforming Chinese herbal medicines for extraction According to the relevant person in charge of the SFDA, if any Chinese herbal medicine or Chinese Herbal Pieces irrelevant to the enterprise's production or entrusted production varieties are found in this inspection, an in-depth investigation will be carried out to find the root At the same time, it will also compare the amount of standard products to be used in the inspection of finished products, semi-finished products, crude drug powder or extract, decoction pieces, medicinal materials, etc with the actual purchase amount and use amount If the access is large, it will be checked to the end.